Interindividual Regulation of the Breast Cancer Resistance Protein/ABCG2 Transporter in Term Human Placentas

被引:24
作者
Bircsak, Kristin M. [1 ]
Moscovitz, Jamie E. [1 ]
Wen, Xia [1 ]
Archer, Faith [4 ]
Yuen, Poi Yu Sofia [4 ]
Mohammed, Moiz [4 ]
Memon, Naureen [4 ]
Weinberger, Barry I. [5 ]
Saba, Laura M. [6 ]
Vetrano, Anna M. [4 ]
Aleksunes, Lauren M. [1 ,2 ,3 ]
机构
[1] Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ USA
[2] Rutgers State Univ, Environm & Occupat Hlth Sci Inst, Piscataway, NJ USA
[3] Rutgers State Univ, Lipid Ctr, Piscataway, NJ USA
[4] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Pediat, New Brunswick, NJ USA
[5] Cohen Childrens Med Ctr New York, Hofstra Northwell Sch Med, New Hyde Pk, NY USA
[6] Univ Colorado, Skaggs Sch Pharm & Pharmaceut Sci, Dept Pharmaceut Sci, Aurora, CO USA
基金
美国国家卫生研究院;
关键词
ARYL-HYDROCARBON RECEPTOR; ABCG2; BCRP; CHEMORESISTANCE PHENOTYPE; BCRP/ABCG2; TRANSPORTER; EXPRESSION; CELLS; GENE; POLYMORPHISMS; PROMOTER; BINDING;
D O I
10.1124/dmd.117.079228
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The breast cancer resistance protein (BCRP/ABCG2) is a maternally-facing efflux transporter that regulates the placental disposition of chemicals. Transcription factors and gene variants are important regulatory factors that influence transporter expression. In this study, we sought to identify the genetic and transcriptional mechanisms underlying the interindividual expression of BCRP mRNA and protein across 137 term placentas from uncomplicated pregnancies. Placental expression of BCRP and regulatory transcription factor mRNAs was measured using multiplex-branched DNA analysis. BCRP expression and ABCG2 genotypes were determined using Western blot and Fluidigm Biomark genetic analysis, respectively. Placentas were obtained from a racially and ethnically diverse population, including Caucasian (33%), African American (14%), Asian (14%), Hispanic (15%), and mixed (16%) backgrounds, as well as unknown origins (7%). Between placentas, BCRP mRNA and protein varied up to 47-fold and 14-fold, respectively. In particular, BCRP mRNA correlated significantly with known transcription factor mRNAs, including nuclear factor erythroid 2-related factor 2 and aryl hydrocarbon receptor. Somewhat surprisingly, single-nucleotide polymorphisms (SNPs) in the ABCG2 noncoding regions were not associated with variation in placental BCRP mRNA or protein. Instead, the coding region polymorphism (C421A/Q141K) correspondedwith 40%-50% lower BCRP protein in 421C/A and 421A/A placentas compared with wild types (421C/C). Although BCRP protein and mRNA expression weakly correlated (r = 0.25, P = 0.040), this relationship was absent in individuals expressing the C421A variant allele. Study results contribute to our understanding of the interindividual regulation of BCRP expression in term placentas and may help to identify infants at risk for increased fetal exposure to chemicals due to low expression of this efflux protein.
引用
收藏
页码:619 / 627
页数:9
相关论文
共 42 条
[1]   Promoter characterization and genomic organization of the human breast cancer resistance protein (ATP-binding cassette transporter G2) gene [J].
Bailey-Dell, KJ ;
Hassel, B ;
Doyle, LA ;
Ross, DD .
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION, 2001, 1520 (03) :234-241
[2]  
Basseville A, 2014, WILEY SER DRUG DISC, P187
[3]   The effect of acetaminophen on the expression of BCRP in trophoblast cells impairs the placental barrier to bile acids during maternal cholestasis [J].
Blazquez, Alba G. ;
Briz, Oscar ;
Gonzalez-Sanchez, Ester ;
Perez, Maria J. ;
Ghanem, Carolina I. ;
Marin, Jose J. G. .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 2014, 277 (01) :77-85
[4]  
Boccia LM, 1996, MOL CELL BIOL, V16, P1929
[5]   Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump [J].
Burger, H ;
van Tol, H ;
Boersma, AWM ;
Brok, M ;
Wiemer, EAC ;
Stoler, G ;
Nooter, K .
BLOOD, 2004, 104 (09) :2940-2942
[6]   Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression [J].
Cha, Pei-Chieng ;
Mushiroda, Taisei ;
Zembutsu, Hitoshi ;
Harada, Hiromasa ;
Shinoda, Noriyuki ;
Kawamoto, Shunji ;
Shimoyama, Rai ;
Nishidate, Toshihiko ;
Furuhata, Tomohisa ;
Sasaki, Kazuaki ;
Hirata, Koichi ;
Nakamura, Yusuke .
JOURNAL OF HUMAN GENETICS, 2009, 54 (10) :572-580
[7]   Pharmacogenetics of ABCG2 and adverse reactions to gefitinib [J].
Cusatis, George ;
Gregorc, Vanesa ;
Li, Jing ;
Spreafico, Anna ;
Ingersoll, Roxann G. ;
Verweij, Jaap ;
Ludovini, Vienna ;
Villa, Eugenio ;
Hidalgo, Manuel ;
Sparreboom, Alex ;
Baker, Sharyn D. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (23) :1739-1742
[8]   ABCG2 pharmacogenetics: Ethnic differences in allele frequency and assessment of influence on irinotecan disposition [J].
de Jong, FA ;
Marsh, S ;
Mathijssen, RHJ ;
King, C ;
Verweij, J ;
Sparreboom, A ;
McLeod, HL .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5889-5894
[9]   Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene [J].
Ee, PLR ;
Kamalakaran, S ;
Tonetti, D ;
He, XL ;
Ross, DD ;
Beck, WT .
CANCER RESEARCH, 2004, 64 (04) :1247-1251
[10]   Transport of glyburide by placental ABC transporters: Implications in fetal drug exposure [J].
Gedeon, C. ;
Behravan, J. ;
Koren, G. ;
Piquette-Miller, M. .
PLACENTA, 2006, 27 (11-12) :1096-1102